Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs adalimumab biosimilar in active ankylosing spondylitis
jRCT2080224045Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, single-blind trial of secukinumab in ankylosing spondylitis (AS) (2 arms), sponsored by Novartis. Primary endpoint: Radiographic progression at 104 weeks. Started Sep 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on jRCT2080224045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224045.